Tine A Baekdal (Tine Baekdal, Tine A Bækdal)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Top Venues

Diabetes, obesity & metabolism

Clinical pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Maria Buur Nordskov Gabe, Rainard Fuhr, Angela Sinn, Astrid Eliasen, Kasper K Berthelsen, Anja B Kuhlman, Tine A Baekdal, Ayna B Nejad
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes, obesity & metabolism (2024)
Panpan Xie, Morten T Abildlund, Tine A Baekdal, Xuemei He, Yassine K Lyauk, Usha Rani H Patted, Zu Ning, Aixin Shi
A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects. Diabetes, obesity & metabolism 26 (8) (2024)
Panpan Xie, Morten T Abildlund, Tine A Baekdal, Xuemei He, Yassine K Lyauk, Usha Rani H Patted, Zu Ning, Aixin Shi
A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects. Diabetes, obesity & metabolism 26 (8) (2024)
Panpan Xie, Morten T Abildlund, Tine A Baekdal, Xuemei He, Yassine K Lyauk, Usha Rani H Patted, Zu Ning, Aixin Shi
A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects. Diabetes, obesity & metabolism (2024)
Marloes van Hout, Pablo Forte, Thomas Bo Jensen, Cristina Boschini, Tine A Baekdal
Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects. Clinical pharmacokinetics (2023)
Marloes van Hout, Pablo Forte, Thomas Bo Jensen, Cristina Boschini, Tine A Baekdal
Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects. Clinical pharmacokinetics (2023)
Marloes van Hout, Pablo Forte, Thomas Bo Jensen, Cristina Boschini, Tine A Baekdal
Correction to: Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects. Clinical pharmacokinetics (2023)
Kirsten Dahl, Ashley Brooks, Firas Almazedi, Søren Tetens Hoff, Cristina Boschini, Tine A Baekdal
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes, obesity & metabolism 23 (7) (2021)
Kirsten Dahl, Tine A Baekdal
Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al. Diabetes, obesity & metabolism 23 (10) (2021)
Catherine Gibbons, John E Blundell, Søren Tetens Hoff, Kirsten Dahl, Robert Bauer, Tine A Baekdal
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes, obesity & metabolism 23 (2) (2020)